News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Carmenta Bioscience to Develop Serum Diagnostic Test for Preeclampsia From Stanford University



1/25/2013 9:01:55 AM

PALO ALTO, Calif.--(BUSINESS WIRE)--Carmenta Bioscience, Inc., a privately held medical technology company focused on maternal and fetal health, today announced it has acquired the option for a worldwide, exclusive license from Stanford University to develop a set of tests enabling physicians to better diagnose and predict preeclampsia. Preeclampsia is a leading cause of preterm birth and maternal/fetal death, arising in 5-8% of pregnant mothers and characterized by high blood pressure and protein in the urine after week 20 of pregnancy.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES